Výsledky vyhledávání - "Joanna, Udo de Haes"

Pharmacokinetics and Tolerability of Letermovir Coadministered With Azole Antifungals (Posaconazole or Voriconazole) in Healthy Subjects

Autor: Joanna Udo de Haes, Marian Iwamoto, Azra Hussaini, Fang Liu, Carolyn R. Cho, Melissa Drexel, Sreeraj Macha, Bhavna Kantesaria, William L. Marshall, Heather R. Jordan, Arne van Schanke, Joan R. Butterton, Karsten Menzel, Ellen G. J. Hulskotte, Christine Tsai, Jacqueline B. McCrea

Publikováno v: The Journal of Clinical Pharmacology. 58:897-904

Letermovir is a human cytomegalovirus terminase inhibitor for cytomegalovirus infection prophylaxis in hematopoietic stem cell transplant recipients. Posaconazole (POS), a substrate of glucuronosyltransferase and P-glycoprotein, and voriconazole (VRC

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aef586af8a1dede86fb239dff6c0f509
https://doi.org/10.1002/jcph.1094

Zobrazit plný text záznamu

Pharmacokinetics of sugammadex in subjects with moderate and severe renal impairment

Autor: Christina Reitmann, Dennis Wolford, Kenneth C. Lasseter, David E. Gutstein, Rebecca E Wrishko, William D. Hanley, Joanna Udo de Haes, K Chris Min, Thomas Marbury

Publikováno v: Int. Journal of Clinical Pharmacology and Therapeutics.

AIMS Sugammadex rapidly reverses moderate and deep rocuronium- or vecuronium-induced neuromuscular blockade at doses of 4 mg/kg and 2 mg/kg, respectively. Sugammadex is renally eliminated. This study evaluated the pharmacokinetics of sugammadex in su

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2458f78b23b93032921eaad015b19a64
https://doi.org/10.5414/cp203025

Zobrazit plný text záznamu

A randomised trial of the effect of the glycine reuptake inhibitor Org 25935 on cognitive performance in healthy male volunteers

Autor: Joanna Udo de Haes, Sue Wilson, David J. Nutt, David M Christmas, A. Rich, Alison Diaper, Suzanne Phillips, Magnus Sjögren

Publikováno v: Human Psychopharmacology: Clinical and Experimental. 29:163-171

Objective Cognitive impairment is integral to many neurological illnesses. Specific enhancement of glutamatergic transmission may improve memory and learning. Org 25935 increases the synaptic availability of glycine, an obligate co-agonist with gluta

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::cf50d4f541b6a792bead0709c2f24da3
https://doi.org/10.1002/hup.2384

Zobrazit plný text záznamu

Early stage development of the glycine-1 re-uptake inhibitor SCH 900435: central nervous system effects compared with placebo in healthy men

Autor: Marieke L. de Kam, Joanna Udo de Haes, Joop M. A. van Gerven, Chris Hogg, Adam F. Cohen, Ingrid M C Kamerling, Marieke Liem-Moolenaar, Graham E. Holder, Pierre Peeters, Huub Jan Kleijn, Edwin Spaans, Kari L. Franson

Publikováno v: British Journal of Clinical Pharmacology. 75:1455-1467

Aims To report the first three studies with SCH 900435, a selective glycine-1 re-uptake inhibitor in development for treating schizophrenia, using systematic evaluations of pharmacodynamics to understand the observed effects. Methods Three double-bli

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d6522edbf6d18bc472f209ce35f402b7
https://doi.org/10.1111/bcp.12015

Zobrazit plný text záznamu

Glycine Transporter Inhibitor Attenuates the Psychotomimetic Effects of Ketamine in Healthy Males: Preliminary Evidence

Autor: Mohini Ranganathan, Joanna Udo de Haes, Pierre Peeters, Nagendra M. Singh, Deepak Cyril D'Souza, Jacques Schipper, Brian Pittman, Jacqueline Elander, Michelle Carbuto, Magnus Sjögren

Publikováno v: Neuropsychopharmacology. 37:1036-1046

Enhancing glutamate function by stimulating the glycine site of the NMDA receptor with glycine, D-serine, or with drugs that inhibit glycine reuptake may have therapeutic potential in schizophrenia. The effects of a single oral dose of cis-N-methyl-N

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b2804639811abd8a6c8ec287ead1e2d0
https://doi.org/10.1038/npp.2011.295

Zobrazit plný text záznamu

Early stage development of the glycine-1 re-uptake inhibitor SCH 900435: central nervous system effects compared with placebo in healthy men

Autor: Marieke, Liem-Moolenaar, Pierre, Peeters, Ingrid M C, Kamerling, Chris, Hogg, Graham, Holder, Huub Jan, Kleijn, Edwin, Spaans, Joanna, Udo De Haes, Marieke L, de Kam, Kari L, Franson, Adam F, Cohen, Joop M A, van Gerven

Publikováno v: British journal of clinical pharmacology. 75(6)

To report the first three studies with SCH 900435, a selective glycine-1 re-uptake inhibitor in development for treating schizophrenia, using systematic evaluations of pharmacodynamics to understand the observed effects.Three double-blind, placebo-co

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::cf8905ca062d332cfb0b4a8835d0e6c7
https://pubmed.ncbi.nlm.nih.gov/23116363

Zobrazit plný text záznamu

A randomised trial of the effect of the glycine reuptake inhibitor Org 25935 on cognitive performance in healthy male volunteers

Autor: David, Christmas, Alison, Diaper, Sue, Wilson, Ann, Rich, Suzanne, Phillips, Joanna, Udo de Haes, Magnus, Sjogren, David, Nutt

Publikováno v: Human psychopharmacology. 29(2)

Cognitive impairment is integral to many neurological illnesses. Specific enhancement of glutamatergic transmission may improve memory and learning. Org 25935 increases the synaptic availability of glycine, an obligate co-agonist with glutamate at N-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::fedb909591ab9f377691a90631a67f2d
https://pubmed.ncbi.nlm.nih.gov/24424780

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání